✦ LIBER ✦

Periodontal and Serum Protein Profiles in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitor Adalimumab

✍ Scribed by Kobayashi, Tetsuo; Yokoyama, Tomoko; Ito, Satoshi; Kobayashi, Daisuke; Yamagata, Akira; Okada, Moe; Oofusa, Ken; Narita, Ichiei; Murasawa, Akira; Nakazono, Kiyoshi; Yoshie, Hiromasa

Book ID: 123615097
Publisher: American Academy of Periodontology
Year: 2014
Tongue: English
Weight: 474 KB
Volume: 85
Category: Article
ISSN: 0022-3492
DOI: 10.1902/jop.2014.140194

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Periodontal Therapy Reduces the Severity

Periodontal Therapy Reduces the Severity of Active Rheumatoid Arthritis in Patients Treated With or Without Tumor Necrosis Factor Inhibitors

✍ Ortiz, P.; Bissada, N.F.; Palomo, L.; Han, Y.W.; Al-Zahrani, M.S.; Panneerselvam 📂 Article 📅 2009 🏛 American Academy of Periodontology 🌐 English ⚖ 462 KB

Anti-Tumor Necrosis Factor-Alpha Therapy

Anti-Tumor Necrosis Factor-Alpha Therapy and Periodontal Parameters in Patients With Rheumatoid Arthritis

✍ Mayer, Yaniv; Balbir-Gurman, Alexandra; Machtei, Eli E. 📂 Article 📅 2009 🏛 American Academy of Periodontology 🌐 English ⚖ 565 KB

Reduction in serum levels of substance P

Reduction in serum levels of substance P in patients with rheumatoid arthritis by etanercept, a tumor necrosis factor inhibitor

✍ Tomoki Origuchi; Naoki Iwamoto; Shin-ya Kawashiri; Keita Fujikawa; Toshiyuki Ara 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 334 KB

Tumour necrosis factor inhibitors: risks

Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis

✍ L. Roberts; G. J. McColl 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 194 KB

Effects of anti-tumor necrosis factor th

Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis

✍ Martin Soubrier; Pierre Jouanel; Sylvain Mathieu; David Poujol; Delphine Claus; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 107 KB

Individualized monitoring of drug bioava

Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab

✍ Klaus Bendtzen; Pierre Geborek; Morten Svenson; Lotta Larsson; Meliha C. Kapetan 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 2 views

## Abstract ## Objective Infliximab, an anti–tumor necrosis factor α (anti‐TNFα) antibody, is effective in the treatment of several immunoinflammatory diseases. However, many patients experience primary or secondary response failure, suggesting that individualization of treatment regimens may be b